Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Apr. 30];6(6):s45. Available from: https://skin.dermsquared.com/skin/article/view/1800